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Contrast-enhanced (CE) MRI was used to monitor breast cancer response to neoadjuvant chemotherapy. Patients underwent CE
MRI before and after therapy, together with conventional assessment methods (CAM). CE MRI was carried out at 1.5T in the
coronal plain with 3D sequences before and after bolus injection. An expert panel determined chemotherapy response using both
CE MRI and CAM. Histopathological response in the surgical specimen was then used to determine the sensitivity and specificity of
CE MRI and CAM. In total, 67 patients with 69 breast cancers were studied (mean age of 46 years). Tumour characteristics showed a
high-risk tumour population: median size 49mm: histopathological grade 3 (55%): oestrogen receptor (ER) negative (48%).
Histopathological response was as follows: – complete pathological response (pCR) 17%; partial response (pPR) 68%; no response
(NR) 15%. Sensitivity of CAM for pCR or pPR was 98% (CI 91–100%) and specificity was 50% (CI 19–81%). CE MRI sensitivity was
100% (CI 94–100%), and specificity was 80% (CI 44–97%). The absolute agreement between assessment methods and
histopathology was marginally higher for CE MRI than CAM (81 vs 68%; P¼0.09). In 71%, CE MRI increased diagnostic knowledge,
although in 20% it was judged confusing or incorrect. The 2nd MRI study significantly increased diagnostic confidence, and in 19%
could have changed the treatment plan. CE MRI persistently underestimated minimal residual disease. In conclusion, CE MRI of breast
cancer proved more reliable for predicting histopathological response to neoadjuvant chemotherapy than conventional assessment
methods.
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Breast cancer treatment has advanced over the past two decades,
achieving a better outcome for women (Peto et al, 2000). One of
several factors contributing to improved survival is chemotherapy,
which is now widely used particularly for women under 50 years
and those with high-grade ER negative or lymph node-positive
tumours. When chemotherapy is given prior to definitive surgical
treatment, there are various potential benefits (Valero et al, 2002):
  Primary tumour response provides evidence of responsiveness
to the chosen chemotherapeutic agent and predicts local control
(Chollet et al, 2002)
  A large tumour may become amenable to breast-conserving
surgery (Makris et al, 1997; Fisher et al, 1998)
  An ineffective therapeutic agent may be changed to one with
clinical effect, or surgery may be advanced, thereby saving cost
and patient suffering (Sotiriou et al, 2002; Pusztai et al, 2003)
There is no evidence of benefit in overall or disease-free survival
as a result of the use of chemotherapy in the neoadjuvant setting
(Fisher et al, 1998; Green and Hortobagyi, 2002). Marginally
statistically significant treatment-by-age interactions appear to be
emerging for survival and disease-free survival, suggesting that
younger patients may benefit from preoperative therapy, whereas
the reverse may be true for older patients (Wolmark et al, 2001). It
is logical to initiate systemic treatment early in those patients with
a high risk of micro-metastatic disease and to monitor the
response. Conventional tools to monitor response include
measurement of maximum tumour diameter with callipers; loss
of signs of inflammation and reduction in lymph node size. Serial
core biopsy has been used to show changes in tissue morphology
by standard histological criteria and more recently with molecular
markers (Sotiriou et al, 2002; Pusztai et al, 2003). Response of the
primary tumour or regional nodes may be monitored radiologi-
cally with mammography or ultrasound (Helvie et al, 1996;
Vinnicombe et al, 1996; Huber et al, 2000); and newer imaging
modalities (Mankoff et al, 1999; Tiling et al, 2001), such as
contrast-enhanced (CE) MRI are being increasingly used. The
literature contains many single institution reports of the use of
breast MRI for monitoring tumour response or predicting tumour
extent prior to surgery. Table 1 summarises the literature to date
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lon the use of breast MRI to monitor neoadjuvant chemotherapy. It
can be seen from the right-hand column of this table that the
findings have varied very substantially. Breast MRI appears to hold
promise for this purpose, and provides measurements that are
more accurate than clinical or ultrasound assessment (Davis et al,
1996; Esserman et al, 1999). It is important to know whether
predictions of residual tumour are accurate. Breast MRI has good
sensitivity for invasive tumour but relatively poor specificity in
untreated disease (Mussurakis et al, 1996). The limitations are
more apparent for invasive lobular carcinoma and in situ (Kinkel
and Hylton, 2001). Contrast-uptake characteristics have been
shown to be altered by chemotherapy, which may potentially
diminish sensitivity and impair specificity (Rieber et al, 1997).
Contrast uptake characteristics have been used to give an early
indication of tumour response using innovative functional MR and
computer methods (Padhani, 2002; Delille et al, 2003). It is
therefore an open question whether CE MRI would be helpful in
monitoring response, or whether limitations emerging from
studies undertaken concurrent with this one would make it
unreliable.
In this study, we have investigated the impact of breast MRI on
decision-making. Almost all of our patients underwent mastect-
omy after neoadjuvant chemotherapy. It is therefore possible to
correlate the extent of tumour detectable on breast MRI following
chemotherapy with histopathology of the mastectomy specimen.
The aims of our study were:
1. To determine whether CE MRI is an accurate indicator of
tumour response to neoadjuvant chemotherapy in comparison
to the histopathology gold standard.
2. To assess whether CE MRI increases the diagnostic confidence
above that achieved by conventional assessment methods
(CAM) (i.e. clinical examination, ultrasound and mammogra-
phy)
3. To determine whether CE MRI can accurately identify a subset
of patients who might be suitable for breast-conserving surgery
following neoadjuvant chemotherapy.
PATIENTS AND METHODS
Patients and chemotherapy
The study had approval from the Local Research Ethics Committee
for Cambridgeshire, and all women had given informed consent to
participate. It is a retrospective review of 67 women with CE-MRI
before and after neoadjuvant chemotherapy for breast cancer. The
first 30 women were recruited between 1997 and 2001 to a
prospective pilot study of CE MRI. The remaining 37 women were
consecutively enroled once CE MRI monitoring became the
standard of care at our centre in 2001. The decision to give
neoadjuvant therapy was made by a multidisciplinary team, and in
general included women less than 60 years with large, inflamma-
tory or high-grade tumours. Chemotherapeutic regimens used in
this series varied according to whether patients were treated in
ongoing clinical trials (Appendix A). All cases had undergone
mammography, ultrasound and core biopsy prior to the decision
to treat with neoadjuvant chemotherapy, and the results of these
tests were used by the team to determine which trials they should
enter.
Contrast enhanced MRI (CE MRI)
The patients had two MRI studies, at the start of treatment and
prior to surgery. The initial MRI study was usually undertaken
prior to the first course of chemotherapy except in occasional cases
where limitations of access to MRI resulted in imaging after the
first treatment had been given. The 2nd MRI study was performed
after all chemotherapy and prior to surgery. The studies were
undertaken on a 1.5T magnet from GE Signa Echospeed, which
was upgraded in 2002 with Excite software. The MRI technique is
similar to that described for the MARIBS study (Brown et al, 2000),
with the exceptions that the dose of gadolinium was
0.16mmolkg
 1 body weight, and no proton density study was
undertaken in our study (Scanning protocol – Appendix B). MRI
interpretation used a synthesis of dynamic and morphological
Table 1 Existing literature on the use of breast MRI to monitor response to chemotherapy
Author Origin Year Number Measurement Pathology response
Knopp et al (1994) Heidelberg, Germany 1994 Three case studies Promising prediction
Gilles et al (1994) Villejuif, France 1994 18 (15 out of 18) 83% Highly predictive of
residual tumour
Abraham et al (1996) Dallas & Little Rock, USA 1996 39 MRI correctly predicted residual disease in
30 out of 31 (97%)
Rieber et al (1997) Ulm, Germany 1997 13 Underestimates residual tumour
Trecate et al (1998) Milano, Italy 1998 27 Valid tool for monitoring response
Tsuboi et al (1999) Kochi, Japan 1999 31 Valuable for predicting response and
margins
Weatherall et al (2001) Dallas, TX, USA 2001 22 Cc0.93MR, 0.63 mam Accurate assessment of residual tumour
Nakamura et al (2001) Tokyo, Japan 2001 15 Predict possibility of WLE. Mapping of
dendritic tumours
Drew et al (2001) Hull, UK 2001 17 Sensitivity 100% Accurate method of predicting residual
tumour
Esserman et al (2001) UCSF 2001 33 Patterns of tumours identified
Partridge et al (2002) UCSF 2002 52 R0.89, C0.60 MRI detected all residual disease
Balu-Maestro et al (2002) Nice, France 2002 60 in 51 women Valuable tool for size & multifocality prior
to surgery
Rieber et al (2002) Ulm, Germany 2002 58 Accuracy NR 83.3%, PR 82.4% Good for assessing response to chemo,
unreliable in CR cases where 66.7% had
residual tumour
Cheung et al (2003) Kwei San, Taiwan 2003 33 Useful to assess early response and predict
tumour size change
Delille et al (2003) Harvard, USA 2003 14 EFPcount accurate measure (Po.02) Extraction flow product as marker of
tumour response
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lfeatures, including the pattern of contrast uptake and washout
characteristics, and the studies were examined at the console to
allow dynamic contrast enhancement curves at any point in the 3D
volume of the dynamic acquisition. The studies were reported by
radiologists and presented to the multidisciplinary team for
decisions on patient management.
Conventional methods of assessment
All patients had a clinical assessment prior to each of six cycles of
chemotherapy. This included calliper measurement of tumour size,
degree of inflammation and size of palpable axillary nodes. All
patients underwent mammography, ultrasound and core biopsy
for diagnosis. Ultrasound was carried out after three and six cycles
of chemotherapy. Conventional breast imaging comprised mam-
mography, ultrasound and core biopsy according to the guidelines
of the United Kingdom National Health Service Breast Screening
Programme (NHSBSP) (Wilson et al, 2001).
Surgery
Surgery normally took place less than 4 weeks after the last course
of chemotherapy. All patients underwent either mastectomy or
wide local excision (WLE) with axillary lymph node dissection.
Histopathological response
Response to treatment was scored by standard UICC (Therasse
et al, 2000) categories of Complete Response (CR), Partial
Response (PR), Non-Response (NR), Disease Progression (DP).
The reports were produced at the time of clinical care without
particular knowledge of the MRI findings. It should be noted that
after chemotherapy the criteria for grading cannot be applied, and
so when grades are given here they are based on core biopsy
(Harris et al, 2003).
There are no recognised standard criteria for grading of
histological response following primary chemotherapy. In this
study, mastectomy specimens were handled according to the
NHSBSP guidelines (NHSBSP publication No. 3, 1995). In addition,
in those cases where no macroscopic tumour could be identified,
extensive sampling of the original tumour site (as identified by
imaging methods and clinical examination prior to treatment) was
performed.
On histological examination, where distinct in situ and invasive
tumour was identified this was morphologically compared with
tumour seen on the original core biopsy. The ratio of tumour cell
mass to surrounding tissue was evaluated. If degenerative changes
within tumour cells were present this was noted. The nature of the
tissue surrounding tumour cells was noted, viz was it a cellular
stroma similar to that seen in the original biopsy or was it
inflamed, hypocellular scar tissue.
Thus:
(1) No histological response. Tumour resembling that in the
original core biopsy was present and it extended within the breast
tissue for the same or a greater distance than originally estimated
by imaging and clinical examination. The nature of the tissue
surrounding the tumour was cellular and did not resemble bland
scar tissue.
(2) Complete histological response. Absence of invasive carcino-
ma cells/or o1single, degenerate carcinoma cell/10 high-power
fields. Absence of in situ carcinoma.
(3) Partial histological response. Tumour resembling that in the
original core biopsy but which was considerably reduced in size (it
is necessary to approximate size parameters used in clinical
response staging). Presence of residual microscopic foci of invasive
carcinoma but with reduced tumour cell/stroma ratio or residual
pure in situ carcinoma.
Assessment of sensitivity, specificity of conventional
assessment methods and CE MRI
Original records were used to score clinical response using CAM,
CE MRI response and histopathological response, and from these
sensitivity and specificity were calculated. Pathological response
was regarded as the gold standard against which all evaluations of
response were measured.
Assessment of diagnostic impact and confidence of
knowledge
For the purposes of this study, all cases were reviewed by the
multidisciplinary team and a research form completed to record
the diagnostic impact. The review team consisted at minimum of a
radiologist, a surgeon, an oncologist and a histopathologist, all
expert in management of breast disease. The multidisciplinary
review procedure is shown in Figure 1. The clinical notes were
examined for the clinical findings recorded at the time of clinical
care. The mammograms and ultrasound images with their original
reports were presented as in a standard multidisciplinary team
meeting. The MRI studies were presented to the clinical team using
the images and reports taken at the time of clinical care of the
patients. The multidisciplinary team were unaware of the
histopathology findings when they interpreted the results of the
MRI and other presurgical examinations. The pathology was
presented from the histological report at the time of clinical care,
and did not take particular account of MRI knowledge. The added
value of MRI imaging was given a score 1y6 (Figure 2) by the
team, taking into account the additional contribution made by the
MRI study beyond that available with conventional breast imaging
(Shuman et al, 1985a,b). A visual analogue scale was used to
record confidence of knowledge with conventional breast imaging
alone and with the addition of MRI (Blanchard et al, 1997).
Confidence of knowledge included knowledge of the size, the
contour, the extent and the suitability for any form of surgery. The
two measures, added value and confidence of knowledge are
complementary, since confidence of knowledge is an important
aspect of value to a clinician. These are subjective clinical
judgements.
Statistical analyses
Proportions in independent samples were compared using Fisher’s
exact test or linear by linear w
2 test as appropriate. Parametric and
nonparametric paired comparisons of mean and median values
were performed using the paired t-test and McNemar test,
respectively. The relationship between initial tumour size and
subsequent tumour response was assessed using one-way analysis
of variance. Statistical significance was accepted at the conven-
tional Po0.05 threshold.
RESULTS
The study evaluated 69 cancers in 67 women including two
bilateral cases. In all, 67 cancers were treated with mastectomy and
two with WLE. The mean age of the patients at the time of the 1st
MRI was 46.2 (range 28 to 62 years). On initial radiological
examination, the median size of the 69 tumours was 49.0mm
(range 9–100mm). The core biopsy demonstrated that six (9%)
tumours were grade 1, 25 (36%) grade 2 and 38 (55%) grade 3.
These therefore represent relatively large, poor prognosis cancers
in younger women. In total, 36 (52%) tumours were oestrogen
receptor (ER) positive, and 33 (48%) ER negative, 21 out of 26
(81%) patients where the progesterone receptor (PR) status was
recorded were PR negative. At definitive surgery, patients had a
median of 13 nodes retrieved (range 0–42); 17 patients (25%) had
more than four nodes involved, 23 (33%) had between one and
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lfour nodes involved, and 29 (42%) were node negative. In all, 12
(17%) patients presented with inflammatory cancers, 31 (45%)
were known to be multifocal or diffuse lesions by their imaging or
clinical findings, and a further 16 (23%) lesions were close to the
nipple–areolar complex. After the initial clinical and radiological
evaluation, a total of 52 (75%) tumours were considered not
suitable for breast conservation within the protocols of our unit,
where skin involvement by inflammation, very large size, multi-
focality and proximity to the nipple–areolar complex are all
viewed as reasons for not using breast-conserving surgery. The
median period between the 1st and 2nd MR imaging was 119 days
(range 48–165 days). The median period between the 2nd MR and
surgery was 24 days (range 2–77 days). The neoadjuvant
chemotherapy included cases in trials, notably Anglo-Celtic 2,
and cases off trial with a variety of regimens (Appendix A).
Estimation of response
Based on the gold standard histopathology findings, 12 lesions
(17%) had complete response, 47 (68%) had partial response, 10
(15%) had no response following neoadjuvant chemotherapy
(Table 2). There was no significant association between the grade
of the tumour and the extent of disease response following
chemotherapy. In total, 24% (nine out of 38) of grade 3 tumours
had complete response to chemotherapy compared to 12% (three
out of 25) of grade 2 tumours and 0% (zero out of six) of grade 1
tumours (P¼0.10). Four out of 36 (11%) ER-positive tumours
exhibited complete response at pathology compared to six out of
21 (29%) of tumours that were ER- and PR negative (P¼0.15).
Lesions that did not respond or progressed after neoadjuvant
chemotherapy were slightly, but nonsignificantly, larger than
lesions that exhibited partial or complete response (mean size 56 vs
49 vs 48mm; P¼0.56). Tumour response was clearly related to the
extent of node involvement. In all, 97% (28 out of 29) of lesions
with no node involvement had complete or partial response
compared to 87% (20 out of 23) of lesions with between one and
four positive nodes and 65% (11/17) lesions with more than four
involved nodes (Po0.01).
Conventional assessment methods and MRI in the
estimation of tumour response
The clinical assessment of tumour response agreed with the
pathology assessment in 47 out of 69 tumours (68%) (Table 2).
CAM underestimated the degree of response in four cases, and
overestimated the degree of response in 18 cases. In one case, a
tumour which was categorised as completely responsive based on
the clinical data had no response evident at pathological
examination. CAM correctly identified 58 out of 59 lesions with
complete or partial response based on pathology findings
(sensitivity 98%; 95% confidence interval (CI) 91–100%). How-
ever, five out of 10 tumours with no response were incorrectly
categorised as complete or partial response on the clinical
assessment (specificity 50%; CI 19–81%).
There was agreement between MRI findings and the pathology
findings in 56 out of 69 lesions (81%) (Table 3). The imaging
findings underestimated the effect of chemotherapy in one case
where disease appeared to have progressed on CE MRI, but where
pathology results indicated no response. In a further 12 cases, MRI
overestimated the response to therapy. The sensitivity (100%; CI
94–100%) and specificity (80%; CI 44–97%) of MRI for
identifying complete or partially responsive tumours were higher
than for the clinical assessment alone. The absolute agreement
between MRI and pathology findings was marginally higher than
the agreement between clinical assessment and pathology findings
(81 vs 68%; P¼0.09).
Diagnostic confidence and therapeutic impact after MRI
In the majority of cases, the 2nd MRI study was judged to increase
diagnostic knowledge (470% see Table 4). However, in a
substantial proportion of cases (17% see Table 4) the 2nd MRI
was judged to have reduced diagnostic knowledge. These 12 cases
have been examined in greater detail – see Table 5A.
In the majority of patients the 2nd MRI study did not change the
treatment plan but did increase diagnostic confidence (52%,
Table 4). This confidence was clearly valued by clinicians. Again,
in a substantial minority of cases (20%, Table 4) the MRI findings
Wide local excision = WLE          Contrast enhanced MRI= CE MRI 
Clinical exam
Is WLE possible?
Tumour size 
Conventional imaging
Is WLE possible?
Tumour size 
Histology – gold standard 
Is WLE possible?  
Tumour response  
Neoadjuvant chemotherapy 
1st MRI 
Is WLE possible?  
Tumour size 
2nd Conventional imaging and 
clinical exam 
Is WLE possible?  
Tumour size 
Tumour response 
2nd MRI  
Is WLE possible?  
Tumour size 
Tumour response 
Surgery – mastectomy (n=67)
WLE (n=2)  
Confidence of 
knowledge with 
conventional 
imaging & clinical 
Diagnostic 
impact 1–6 (see 
Figure 2) 
Confidence of 
knowledge with 
CE MRI 
Confidence of 
knowledge with 
conventional 
imaging & clinical
Confidence of 
knowledge with 
CE MRI 
Figure 1 Algorithm for recording findings in the multidisciplinary
meeting.
1 = MR results were confusing or incorrect and stimulated more 
studies to clarify the situation 
2 = MR results were confusing or incorrect but did not stimulate
more studies 
3 = MR results had no impact on original therapy plan 
4= MR result did not cause a change in the original plan but 
increased the confidence in that plan 
5 = MRI results could have caused a measurable change in the 
original plan 
6 = MR results did cause a measurable change in the original
plan.
Figure 2 Value of including MRI imaging.
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lwere thought to be confusing or incorrect. In the majority of these
cases, the problem stemmed from the MRI study underestimating
the amount of residual tumour by suggesting a complete response
when, in fact, there were residual invasive tumour cells or DCIS.
These cases have been examined more closely and the findings set
out in Table 5A. In a further 19% of cases (Table 4) the 2nd MRI
either did, or had the potential to alter the treatment plan. These
cases have been summarised in Table 5b. The reasons included a
contralateral nonpalpable tumour, complete response that could
have allowed breast conservation, demonstration of nonresponse,
demonstration of a single focus where multifocality was suspected.
The mean diagnostic confidence for all patients significantly
increased from 5.8 pre-2nd MRI to 7.9 post-2nd MRI (Po0.01;
Table 4).
Surgical findings indicated that WLE would not have been
possible following neoadjuvant chemotherapy in 47 out of 69
lesions (Table 4). In 35 out of these 47 cases, both conventional
assessment and MRI correctly predicted the need for mastectomy.
The remaining 12 cases were evenly split between cases where
conventional assessment incorrectly predicted WLE was possible
(4), cases where MRI incorrectly predicted WLE was possible (4),
and cases were both presurgery evaluations incorrectly suggested
that breast-conserving surgery was possible (4).
In all, 10 out of the 22 lesions (46%) where surgical findings
demonstrated that WLE would have been feasible were correctly
identified by both conventional assessment and MRI (Table 4). In
five cases, MRI correctly contradicted the conventional assessment
by suggesting that WLE was possible. However, in the remaining
seven cases MRI suggested that WLE was possible when surgical
findings indicated that it was not. The overall agreement with
surgical findings regarding the feasibility of WLE was 74% (51 out
of 69) for conventional assessment and 78% (54out of 69) for MRI
(P¼0.44). Cases where the 2nd MRI study disagreed with surgical
findings regarding the possibility of WLE are summarised in more
detail in Table 6.
DISCUSSION
To achieve the objectives of neoadjuvant timing in the use of
chemotherapy, it is necessary to understand the available
preoperative methods of assessing response. Assessment of
response to permit conservation surgery and to judge the
effectiveness of the chemotherapy and the biological responsive-
ness of tumours are both important. Clinical methods have been
unreliable (El-Didi et al, 2000), and there are clear limitations in
the power of mammography (Huber et al, 2000) or ultrasound (for
this purpose, ultrasound is widely used, but very poorly
researched) to provide accurate information. CE breast MRI has
attractions for this purpose, since it has high sensitivity for
Table 2 Comparison of clinical assessment with ultrasound and mammography and pathology rating of tumour response
Conventional assessment methods (CAM) Clinical examination+mammography and ultrasound
Complete response Partial response No response Disease progression
Pathology findings Complete response 9 3 0 0
Partial response 13 33 1 0
No response 1 4 5 0
Disease progression 0 0 0 0
Table 3 Comparison of MRI and pathology rating of tumour response
CE MRI findings
Complete response Partial response No response Disease progression
Pathology findings Complete response 12 0 0 0
Partial response 10 37 0 0
No response 1 1 7 1
Disease progression 0 0 0 0
Table 4 Potential diagnostic and therapeutic impact of 2nd MRI
Impact of MRI N (%)
Diagnostic knowledge with 2nd MRI
Better 49 (71%)
Same 8 (12%)
Worse 12 (17%)
Diagnostic value of 2nd MRI
Confusing or incorrect – extra studies required 0 (0%)
Confusing or incorrect – no extra studies 14 (20%)
No change in treatment plan 6 (9%)
No change in treatment plan – increased diagnostic confidence 36 (52%)
Could have caused change in treatment plan 10 (15%)
Caused change in the treatment plan 3 (4%)
Diagnostic confidence of 2nd MRI
Without 2nd MRI (mean (s.d.)) 5.8 (1.8)
With 2nd MRI (mean (s.d.)) 7.9 (2.0)*
Therapeutic impact of 2nd MRI
WLE possible based on surgery 22/69
MRI agrees with conventional assessment, WLE possible 10 (45%)
MRI agrees with conventional assessment, WLE NOT possible 5 (23%)
MRI disagrees with conventional assessment, suggests WLE
possible
5 (23%)
MRI disagrees with conventional assessment, suggests WLE NOT
possible
2 (9%)
WLE NOT possible based on surgery 47/69
MRI agrees with conventional assessment, WLE possible 4 (9%)
MRI agrees with conventional assessment, WLE NOT possible 35 (75%)
MRI disagrees with conventional assessment, suggests WLE
possible
4 (9%)
MRI disagrees with conventional assessment, suggests WLE NOT
possible
4 (9%)
*Po0.01, paired samples t-test for the difference in confidence pre- and post-2nd
MRI.
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linvasive tumour and is dependent on increase in vessel density and
abnormal diffusion properties of tumour blood vessels for its
mode of visualisation. It is essentially a tomographic technique,
able to give attractive 3D images that can aid surgeons in planning
their operative procedures (Figure 3).
There have been a number of studies testing CE breast MRI for
this purpose, which have been summarised in Table 1. The
conclusions of these studies have varied considerably and several
of them have an up-beat approach that may give surgeons and
oncologists false expectations of the capacity of the technique to be
reliable in all the aspects needed for planning treatment. Our study
is from a single multidisciplinary team in two hospitals, with
clinical work of several experts in each discipline. We have used
the contemporary reports and notes of the cases to assess the
Table 5 Cases in which the 2nd MRI study (A) reduced diagnostic knowledge n¼ 12 and (B) either did or had the potential to alter the treatment plan
n¼13
Case
Age,
years
Clinical size, mm at
start of treatment Grade ER
Quadrants
involved
Spaced out cells
present
DCIS
present cR mR pR Comments
(A)
1
a,b 46 50 1 + Multifoc No No 1 1 2 Underestimates residual
tumour
2
a,b 51 Unmeasurable 2 + Unifocal No No 2 1 2 Underestimates residual
tumour
6
a,b 47 60+ 3 + Subareol No Yes 2 1 2 Underestimates residual
tumour ILC
8
b 41 Unmeasurable 3   Diffuse No Yes 1 2 2 Underestimates residual
tumour
13
b 54 40 2 + Unifocal No Yes 1 1 2 Underestimates residual
tumour
25
b 39 60+ 3   Diffuse No Yes 1 1 3 Underestimates residual
tumour
29
a,b 34 60+ 3   Subareol No Yes 1 1 1 No contrast – failed
injection CR report
30
a 49 60+ 2 + Unifocal Yes Yes 2 1 2 Underestimates residual
tumour DCIS
31
a,b 51 60+ 2 + Multifoc No Yes 2 2 2 Underestimates residual
tumour
32
b 40 45 3   Multifoc No No 2 2 2 Underestimates residual
tumour
34
a 43 30 3   Unifocal No Yes 2 1 1 Residual DCIS
41
a,b 34 60+ 2 + Multifoc No Yes 1 2 2 Underestimates residual
tumour ILC
61
a,b 47 60+ 1 + Multifoc No Yes 2 1 2 Underestimates residual
tumour
63
a,b 60 Unmeasurable 3 + Diffuse No Yes 2 2 3 Underestimates residual
tumour
66
a,b 47 45 3 + Subareol No Yes 2 2 2 Underestimates residual
tumour
78
a,b 28 60+ 2   Unifocal Yes No 2 1 2 Underestimates residual
tumour
(B)
7 52 Unmeasurable 2   Unifocal Yes Yes 1 1 2 Could have endorsed WLE
14 49 40 3   Unifocal No Yes 2 2 2 Better estimate of residual
tumour
21 47 60+ 2 + Subareol No Yes 3 2 2 Could have endorsed WLE
34 43 30 2   Unifocal No Yes 2 1 1 Could have endorsed WLE
DCIS only
37 57 54 1   Multifoc No No 1 1 1 Could have endorsed WLE
44 56 40 3   Unifocal No No 1 2 2 Confirmed residual tumour
52 43 50 2 + Subareol No Yes 2 3 3 Showed nonresponder.
Skin thickening
55 43 30 3 + Unifocal No Yes 1 1 1 Could have endorsed WLE
59 52 40 3 + Unifocal Yes Yes 1 1 1 Could have endorsed WLE
62bilat 49 60+ 2 + Diffuse No Yes 2 2 2 Contralateral tumour
shown
67 33 32 3 + Multifoc No No 2 2 2 Did not confirm
multifocality suspected on
ultrasound. Could have
endorsed WLE
71 37 55 2   Subareol No No 1 1 1 Could have endorsed WLE
Grade Bloom & Richardson grades 1, 2 & 3 (Elston and Ellis, 1991) oestrogen receptor¼ER positive (+), negative ( ). Ductal carcinoma in situ¼DCIS, invasive lobular
carcinoma¼ILC. Quadrants – unifocal, multifocal, diffuse, subareolar position. cR¼clinical response, mR¼MRI response, pR¼pathological response 1¼complete response,
2¼partial response, 3¼static disease, 4¼disease progression. Wide local excision WLE.
aCases in which the 2nd MRI study reduced diagnostic knowledge n¼12.
bCases in
which the MRI findings were thought to be confusing or incorrect n¼14.
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limpact, real or potential, on clinical care provided by a CE MRI
study at the start and end of neoadjuvant chemotherapy. We have
used the histopathological response as the gold standard and since
most of our patients had mastectomy, we have the potential to
judge whether WLE could have been achieved. By using the full
multidisciplinary team in evaluating each case, we hope to have
avoided the bias that might ensue from radiologists alone assessing
their value. Diagnostic and therapeutic impact methodology has
been used for assessment of other new diagnostic procedures
(Shuman et al, 1985b) including MRI (Hollingworth et al, 2000) for
other purposes. We have moulded this methodology to apply to
the present clinical scenario, for example by including an extra
category – ‘MRI results could have caused a measurable change in
the original plan’.
A few patients had their MRI study after the first cycle of
chemotherapy was given, but these cases have not been excluded
because the end points in this analysis relate to the presurgical
MRI findings. The range of length between the 2nd MRI and
surgery is determined by difficulties with scheduling of both
MRI studies and reconstructive surgery in our hospital. The
range of times between 1st and 2nd MRI studies is determined
by the different regimens and patient episodes such as
depression of white count which may have delayed cycles of
chemotherapy. Whether these variations are important to the end
points of this analysis is a matter of speculation, but they relate to
pressures that would apply to real-life use of MRI out of the study
setting. Our patients received a variety of chemotherapeutic
regimens but this should make our CE MRI evaluation gener-
alisable to actual clinical practice where chemotherapy choices
vary. The analysis of the MRI study is not affected by the different
chemotherapy regimens.
We have made the main comparison of sensitivity and
specificity between clinical examination coupled with conventional
breast imaging (mammography and breast ultrasound) and CE
MRI. CE MRI had both better sensitivity and specificity than
clinical measures in conjunction with conventional breast
imaging for detecting complete or partial response. The sensitivity
of conventional methods is high, but there are serious limitations
in specificity. In all, 50% (five out of 10) of patients with
no response on pathology were incorrectly classified as partial
or complete responders on clinical assessment, mammography
and ultrasound. The specificity of CE MRI was higher (eight out
of 10), but, due to the small number of patients who did not
respond to chemotherapy, this result did not reach statistical
significance. Furthermore, CE MRI still gives erroneous results
in a number of cases. This is demonstrated in Table 5a where
it is seen that the commonest limitation of the value of CE
MRI is to underestimate residual tumour when compared
with final pathology. Several authors (Gilles et al, 1994;
Drew et al, 2001; Weatherall et al, 2001; Partridge et al, 2002)
have found very good prediction of residual tumour by
breast MRI, whereas Rieber in two studies had findings similar
to ours (Rieber et al, 1997, 2002). We wish to seek the explanation
for this in greater detail, and will do so by a separate publication
studying the dynamic analysis compared with detailed pathology.
Many of the cases with small amounts of residual tumour have
islands of invasive cells or of DCIS spread across the area
previously occupied by the treated tumour. The contrast uptake of
the CE MRI did not distinguish this minimal residual disease
(MRD) from any background uptake within the glandular tissue of
the breast. The chemotherapeutic agents attenuate the contrast
uptake characteristics, rendering the curves on some occasions
benign in appearance. Clinical assessment of response is based on
the size of the palpable mass and the clinical evidence of reduction
in lymphoedema or in lymph node size. CE MRI was shown here to
be better than these clinical findings even when they are backed up
by ultrasound.
The cases in which CE MRI gave added value are shown in
Table 5b. These are demonstration of unsuspected contralateral
tumour, endorsement of a decision for WLE, better demonstra-
tion of nonresponse by showing skin thickening, better estimate
of residual tumour and proof of unifocal disease. In Table 6,
we have scrutinised the performance of CE MRI in predicting
the possibility of WLE after neoadjuvant chemotherapy. It
was a surprise to us that so few cases were suitable for breast-
conserving surgery from the start, and we do not have the power
here to show whether MRI was helpful in a significant way when
only the cases which from the outset could have been suitable are
considered.
It has been shown that pathological response is predictive
of survival (Kuerer et al, 1999; Amat et al, 2002; Chollet et al,
2002) and that outcome is predicted also by tumour grade
and nodal involvement. It would be useful to know whether
complete response on MRI is predictive of outcome, even when
Table 6 Cases where the 2nd MRI study disagreed with surgical findings regarding the possibility of WLE
Case no.
Age in
years
Radiological
size, mm
Core
biopsy
grade ER
Initial
assessment
allows WLE
MRI2
indicates
WLE
possible
Final
pathology
indicates
WLE
possible
DCIS
present in
final
pathology
Spaced out
cells present
in final
pathology Comments
1 46 60 1 + No No Yes No No 15mm unifocal
4 38 70 2 + No No Yes Yes No 22mm unifocal
14 49 34 3   Yes No Yes Yes No 31mm unifocal
22 44 19 3   No No Yes No No No residual tumour
27 45 35 3 + No No Yes No No No residual tumour
31 51 58 2 + No No Yes Yes No 25mm unifocal
62 49 39 2 + No No Yes Yes No 20mm unifocal
2 51 55 2 + Yes Yes No No No Multifocal
6 47 53 3 + No Yes No Yes No Widespread residual
10 41 51 2 + No Yes No Yes No 41mm residue
11 60 38 3   No Yes No No No Mass+scattered foci
13 54 34 2 + Yes Yes No Yes No Multifocal
29 34 100 3   No Yes No Yes No CR but inflammatory at
outset
38 43 60 2 + No Yes No Yes No Widespread foci
61 47 50 1 + No Yes No Yes No Multifocal
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lit fails to identify isolated foci of malignant cells or residual
DCIS. If response on MRI were to be predictive of survival
or disease-free survival, then this would be a test that gave
predictive information prior to surgery and full pathology.
Many more cases than the present study would be required to
answer this question.
Within this series, the grade 3 and ER negative tumours tended
to have a slightly better probability of complete response than the
lower grade, ER-positive tumours, however neither of these
differences reached statistical significance. A factor to consider
here is the under staging that occurs with core biopsy, where 70%
of cases have been shown to be upstaged between core biopsy and
definitive surgical histology (Harris et al, 2003). After chemother-
apy, we do not have satisfactory grading, and so the grades
discussed here are all from core biopsy. The response rate that has
been recorded cannot be appraised since it is dependent on the
case selection for use of neoadjuvant chemotherapy and the
different regimens in use, neither of which have been made
standard in this study. We are looking at the effectiveness of CE
MRI as a tool for monitoring, not at response rates in themselves.
Our study shows that our MRI findings had very serious
limitations in predicting the possibility of undertaking wide local
excision after neoadjuvant chemotherapy, and that the shortfall
was in both directions and not predictable from any particular
characteristics of the cases. This study also shows how inaccurate
clinical assessment of tumour response is, even when enhanced by
ultrasound or mammography.
Even though our study has shown definite limitations to the
reliability of MRI, the clinical team found that it provided
valuable additional information. The problems with CE MRI are
sufficient to continue to seek improved methods of assessing
tumour response. Functional MRI, PET scanning and molecular
imaging are emerging techniques that may offer more accurate
information.
CONCLUSION
Our study suggests that CE MRI may have better sensitivity and
specificity for predicting complete or partial response than clinical
examination with conventional imaging. Moreover, the absolute
agreement between MRI and pathology findings was marginally
higher than the agreement between clinical assessment and
pathology findings. CE breast MRI is robust in predicting
nonresponse and disease progression. Our clinicians valued
the visual images that are obtained which show tumour response.
They feel that they give additional information – probably by
giving a better measure of size and providing images that help
them to understand the permeative properties of the tumour.
In our series, MRI persistently underestimates residual
malignancy where the tumour is not a single mass, and this may
be a problem in some cases when it is used to predict the
possibility of WLE.
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Figure 3 A subtracted image of a large tumour of the left breast before
and after neoadjuvant chemotherapy. (A) and (B) reconstructed in the
axial plane, (C) and (D) in the coronal plane. The patient was aged 52
years, had a clinically immeasurable tumour involving the nipple and so not
suitable for WLE. It was grade 3, ER positive. She was treated with
adriamycin and cyclophosphamide 6 cycles, off-study. She had a complete
clinical response, but final histology showed residual grade 3 tumour with
associated high-grade DCIS. The MRI studies show the considerable
response, but correctly predicted residual tumour over a substantial
volume, confirmed as over 60mm on final histology.
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Appendix A
See Tables A1 and A2.
Table A1 Chemotherapy regimens in use
n
Doxorubicin/cyclophosphamide six cycles 41
Doxorubicin/docetaxel six cycles 21
Epirubicin four cycles then CMF four cycles 2
Epirubicin four cycles 2
Docetaxel/Herceptin 1
Total 67
Clinical trials (1997–2003): Anglo-Celtic 2 Study: doxorubicin/cyclophosphamide vs
doxorubicin/docetaxel six cycles (Evans et al, 2002). _ Docetaxel/Herceptin
expanded access phase 4 assessment (Howell et al, 2002). Standard off study
treatment: doxorubicin/cyclophosphamide six cycles.
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Case Age Size Infl Gr ER PgR Hist Trial cR mR pR
01 46 60 n 1 + IDC AC2 cCR mPR pPR
02 51 55 n 2 + IDC AC2 cPR mPR pPR
03 51 65 n 3 + IDC cCR mPR pPR
50 40 55 n 3    IDC cCR mPR pPR
46 44 95 n 3    IDC cPR mPR pPR
04 38 70 n 2 + IDC AC2 cPR mPR pPR
05 55 45 n 1 + IDC cPR mPR pPR
06 47 53 n 3 + ILC AC2 cPR mCR pPR
07 52 70 n 2   0 IDC AC2 cCR mCR pPR
51 31 48 n 2+    IDC cPR mCR pCR
08 41 70 y 3    IDC AC2 cCR mPR pPR
10 41 51 n 2 + ILC cPR mPR pPR
11 60 38 n 3   + IDC cPR mPR pPR
12 56 88 y 1 + IDC cNR mNR pNR
42 61 65 n 3    IDC cNR mNR pNR
13 54 34 n 2 + IDC AC2 cCR mCR pPR
41 34 69 y 2 + ILC AC2 cCR mPR pPR
14 49 34 n 3    IDC cPR mPR pPR
40 61 34 n 3 + IDC AC2 cPR mCR pPR
15 54 32 n 3 + IDC AC2 cCR mPR pPR
16 39 53 y 3   0 IDC cNR mDP pNR
59 52 55 n 3 + IDC AC2 cCR mCR pCR
17 49 70 y 2   0 IDC cPR mPR pPR
18 47 49 n 3    IDC AC2 cPR mPR pPR
54 49 69 y 3    IDC AC2 cCR mCR pCR
55 43 35 n 3 + IDC AC2 cCR mCR pCR
19 35 50 n 3   + IDC AC2 cPR mPR pPR
20 45 90 y 2 + IDC cPR mPR pPR
21 47 45 n 2 + IDC AC2 cNR mPR pPR
47 30 n 3   + IDC cPR mNR pNR
22 45 19 y 3    IDC AC2 cPR mCR pCR
23 49 40 n 3    IDC AC2 cPR mPR pPR
43 50 46 n 3    IDC AC2 cPR mPR pPR
39 44 39 n 3 + IDC AC2 cCR mCR pCR
25 39 45 n 3    IDC AC2 cCR mCR pNR
26 33 26 n 3    IDC AC2 cPR mPR pCR
27 45 35 n 3 + IDC cCR mCR pCR
57 47 36 n 3    IDC AC2 cPR mNR pNR
29 34 100 y 3    IDC/
ILC
cCR mCR pCR
30 49 54 n 2 + IDC AC2 cPR mCR pPR
31 51 58 n 2 + IDC AC2 cPR mPR pPR
32 40 44 n 3    IDC AC2 cPR mPR pPR
33 41 90 y 3 + IDC cCR mPR pPR
34 43 30 n 3   0 IDC AC2 cPR mCR pCR
58 59 66 n 3    IDC cPR mPR pPR
35 49 66 n 2 + IDC cNR mNR pNR
36 45 49 n 2 + ILC AC2 cPR mPR pPR
61 45 50 n 3 + IDC AC2 cPR mCR pPR
37 57 64 n 2    ILC AC2 cCR mCR pCR
38 43 60 y 2 + IDC AC2 cCR mPR pPR
Key to column headings: Size¼radiological (mammography and ultrasound) size at diagnosis, inflamm¼inflammatory changes present, grade¼ Bloom and Richardson
nuclear grade (Elston and Ellis, 1991) on core biopsy, ER¼oestrogen receptor status on core biopsy, PgR¼progesterone receptor status, Histology¼core biopsy (CB)
histology, IDC Invasive ductal carcinoma, ILC¼invasive lobular carcinoma, Chemo¼neoadjuvant chemotherapy regimen, cR¼clinical response, mR¼MRI response,
pR¼pathological response, CR¼complete response, PR¼partial response, NR¼nonresponder, DP¼disease progression. AC2¼Anglo-Celtic 2 trial.
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See Table B1.
Table B1 MR pulse sequence protocol for a breast MR examination in use for this study
Sequence type
Repetition
time TR
(ms)
Echo time
TE (MS)
1.5T Flip angle (
0) Matrix size
Number of
slices
Field of
view
(FOV)
(MM)
Pixel size
(mm x mm)
Number of
averages
Acquisition time
(min:s)
Precontrast, high-
resolution 3D T1-
weighted
8.9 4.2 35 512 384 60 340 0.66 0.89 1 2
Dynamic contrast
enhanced, 3D T1-
weighted
a 2 sequences
before contrast
injection and 6 after
8.8 4.2 35 256 256
b 480 340 1.33 1.33
b 18  1.10
Postcontrast, high-
resolution 3D T1-
weighted with fat
suppression
18.9 4.2 35 512 384 60 340 0.66 0.89 1 5
aContrast injection was 0.16mmolkg
 1 body weight with an injection speed of 3mls
 1, given after the second precontrast dynamic sequence.
bThe matrix size is optimised to
ensure that the acquisition time of each 3D image is 70s.
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